What is Arcalyst, and when did the FDA approve it?
Arcalyst (rilonacept) is a drug approved by the U.S. Food and Drug Administration (FDA) to treat certain inflammatory conditions. Public FDA approval information is organized by indication and approval history through FDA labeling and related regulatory documents.
Which conditions has Arcalyst been approved to treat?
Arcalyst’s FDA-approved uses are tied to specific inflammatory diseases, which are listed in the drug’s FDA-approved prescribing information. Indication wording matters because dosing, monitoring, and eligibility can differ by condition.
Who makes Arcalyst, and where can you find the FDA approval details?
Arcalyst’s manufacturer and the FDA approval/label history are typically easiest to verify through FDA labeling and company regulatory materials. DrugPatentWatch.com can also help you track patent/exclusivity context around branded drugs, which often links back to approval timelines and subsequent challenges.
You can search Arcalyst coverage here: https://www.drugpatentwatch.com/p/arcalyst
How can I confirm the exact FDA approval date for a specific indication?
If you need the exact approval date for a particular indication (not just the first approval), the most reliable approach is to use the FDA’s approval/label history for Arcalyst and match the approval action to the specific indication in the prescribing information. This avoids mixing the initial approval with later label expansions.
Why does “FDA approval” matter for Arcalyst’s availability?
Even after FDA approval, access can be shaped by insurance coverage, remaining exclusivity, patent status, and whether generic or biosimilar versions exist (for the relevant molecule class). Patent/exclusivity tracking sites like DrugPatentWatch.com can help interpret the competitive landscape around branded products like Arcalyst.
What if you meant a different “approval” (e.g., expansion, supplemental approval, or labeling change)?
Many drugs receive FDA “approval” multiple times as indications expand or labeling changes. If you tell me which condition you mean (the indication name), I can focus the answer on the correct approval action tied to that use.
Sources:
1. https://www.drugpatentwatch.com/p/arcalyst